Dicer deficiency affects microglial function during demyelination and impairs remyelination

Ajai Tripathi1, Nagendra Kumar Rai1, Aaron Perles1

  • 1Department of Neurosciences, Cleveland Clinic, Cleveland, OH, USA.

PubMed

Insights

Loss of Dicer1 in microglia amplifies inflammation and impairs myelin repair in demyelinating diseases. This highlights Dicer1 as a potential therapeutic target for promoting central nervous system repair.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Microglia are crucial for central nervous system (CNS) homeostasis and repair in demyelinating diseases.
  • Dysregulated microglial function exacerbates inflammation and hinders repair in conditions like multiple sclerosis.

Purpose of the Study:

  • To investigate the role of Dicer1, essential for microRNA biogenesis, in microglial function during demyelination and remyelination.
  • To understand how Dicer1 deficiency impacts inflammatory responses, debris clearance, and oligodendrocyte support.

Main Methods:

  • Utilized Dicer1-deficient microglia models.
  • Performed transcriptomic analysis to identify affected pathways.
  • Validated protein secretion and cellular interactions.
  • Assessed effects on oligodendrocyte progenitor cell (OPC) differentiation and oligodendrocyte (OL) survival.

Main Results:

  • Dicer1 deficiency in microglia led to heightened inflammation, impaired myelin debris clearance, and disrupted metabolic homeostasis.
  • Transcriptomics revealed upregulated inflammatory pathways (interferon signaling, JAK/STAT) and reduced homeostatic gene expression.
  • Dicer1-deficient microglia secreted increased pro-inflammatory cytokines (IFN-γ, IL-16, CXCL12), hindering remyelination.
  • Failure to support OPC differentiation and increased mature OL apoptosis contributed to remyelination failure.

Conclusions:

  • Dicer1 is a critical regulator of microglial homeostasis and inflammation resolution in the CNS.
  • Dicer1 deficiency exacerbates demyelination and delays remyelination by promoting chronic inflammation and impairing oligodendrocyte support.
  • Targeting Dicer1 in microglia offers a potential therapeutic strategy for demyelinating diseases.